A Phase 2 interventional study of Budesonide/Procaterol, 180/10mcg X1 and Budesonide/procaterol 180/10 mcg X 2 in Asthma, sponsored by Intech Biopharm Ltd.. Completed at 3 sites in Taiwan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2015-06-03.
Sponsored by Intech Biopharm Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Asthma with a site in Taiwan — 13 open to participants now, 18 under way, 4 of them phase 3. Asthma · Taiwan.
Among the 88 studies in Asthma with a site in Taiwan, this one is the 64th largest by enrollment of the 72 interventional ones that give a count, is one of 3 that started in 2013, is one of 16 in phase 2, and was the 26th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →13 of the 88 studies in Asthma with a site in Taiwan are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Taiwan, Argentina, France and 7 more countries
Ages 12–17
AstraZeneca · Sites in Taiwan, Argentina, Egypt and 4 more countries
Ages 18+
Pfizer · Sites in Taiwan, United States, Argentina and 12 more countries
Ages 18–75
AstraZeneca · Sites in Taiwan, United States, Argentina and 18 more countries
Ages 18–75
GlaxoSmithKline · Sites in Taiwan, United States, Belgium and 9 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 274 across the 72 interventional studies, 225 across the 16 observational. Of the 55 that completed or were terminated, 26 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 88 have an industry lead sponsor. The 10 most frequent:
Intech Biopharm Ltd. is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Intech Biopharm Ltd. has 9 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
6 of the studies in Asthma with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06977581PfizerA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | 2027-03-08 |
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT06932263AstraZenecaDose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids | 2027-06-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 88 studies in Asthma with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the study is to evaluate the dose response of SYN006 HFA MDI, which is a combination drug product of budesonide and procaterol hydrochloride, in asthma patients. Patients with mild to moderate asthma will be recruited. There will be two study medication administered in this study. The investigational medication is SYN006 (Budesonide/Procaterol hydrochloride, 180 mcg/10 mcg per inhalation) and the active comparative medication is Ventolin (Salbutamol sulfate 100 mcg per inhalation). The study medication will be administered by oral inhalation with the supervision of the investigator or a qualified staff.
Three treatments will be administered in a patient:
Patients will be received the study treatment according to one of the six treatment sequences according to the randomization schedule:
The efficacy endpoint is
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Mild Persistent:
Moderate Persistent:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HFA MDI, oral inhalation, 180/10mcg, one puff
Drug: Budesonide/Procaterol, 180/10mcg X1
HFA MDI, oral inhalation, two puffs
Drug: Budesonide/procaterol 180/10 mcg X 2
HFA MDI, oral inhalation, 100mcg, two puffs
Drug: Albuterol HFA MDI 100mcg X2
one puff
Also known as: Synbitide
2 puffs
Also known as: Synbitide
HFA MDI, 100mcg, 2 puffs
Also known as: Ventolin
The variation of study medications by the area under curve of FEV1 from 0 to 120 minutes (AUC0-120min ) after inhalation.
Time frame: 5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation
The change in Forced Expiratory Volume in 1 second (FEV1) of study medication.
Time frame: 5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation
The change in Peak Expiratory Flow Rate (PEFR) of study medication.
Time frame: 5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation
The change in Forced Vital Capacity (FVC) of study medication.
Time frame: 5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation
The variation of study medications by the area under curve of PEFR from 0 to 120 minutes (AUC0-120min ) after inhalation.
Time frame: 5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation
The variation of study medications by the area under curve of FVC from 0 to 120 minutes (AUC0-120min ) after inhalation.
Time frame: 5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation
Adverse events, vital signs, abnormal ECG outcome.
Time frame: 5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation
The record gives a start of Feb 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intech Biopharm Ltd.